Abstract:OBJECTIVE:To investigate the effect of small interfering RNA (siRNA) targeting human vascular endothelial growth factor (hVEGF) on A549 cell growth in nude mice and angiogenesis on chorioallantoic membrane (CAM) assay.METHODS:Three pairs of hVEGF siRNA-plasmid and non-silencing-plasmid were constructed, and transfected into A549 cells through lipofectamine 2000, respectively. The most effective pair of hVEGF siRNA-plasmid was selected by ELISA and real-time RT-PCR. A549 cells transfected with selected hVEGF siRNA- plasmid, A549 cells transfected with non-silencing-plasmid and A549 cells without transfection were inoculated into nude mice, respectively. Chick embryos were randomly divided into four groups and CAM was treated by different solutions for 48 h: culture media DMEM as negative control group,un-transfected A549 cell culture supernatants as positive control group, hVEGF siRNA A549 cell culture supernatants as hVEGF siRNA group and nonsilencing siRNA A549 cell culture supernatants as non-silencing siRNA group. The CAMs were harvested on d12 for microscopic assays.RESULT:Compared with control group, hVEGF siRNA-plasmid induced 48% reduction in hVEGF secretion by A549 cells accompanied by 70% reduction in hVEGF mRNA. Compared with non-silencing siRNA group, the mean tumor volume of murine xenograft was reduced by 58% in hVEGF siRNA group; time for xenografts growing to 50 mm(3)was delayed by 5.4 d. hVEGF contents in xenograft were reduced by 54%; but mean doubling time of tumors and the growth rate of tumors were not significantly reduced. In CAM assays, hVEGF content was zero in negative group, and in hVEGF siRNA group that was 40%-44% of non-silencing siRNA group or positive group; vessels branch points of CAM in hVEGF siRNA group or non-silencing siRNA group or positive group were increased by 45%-55% compared with negative group; total vessel length of CAM in hVEGF siRNA group was increased by 53% compared with negative group, while in non-silencing siRNA group or positive group that was increased by 97% or 99%. Compared with negative control group, the proliferation of microvessels was increased when cell culture supernatant with hVEGF was added in hVEGF siRNA group, significant proliferated vessels were observed in non-silencing siRNA group or positive group.CONCLUSION:A plasmid-mediated hVEGF siRNA has been constructed and verified, which can effectively downregulate the expression of hVEGF in human A549 cells, resulting in the inhibition of angiogenesis. hVEGF siRNA can delay initial growth of A549 tumor xenograft but not reduce the growth rate.

VEGF Sirna Delivered by Polycation Liposome-Encapsulated Calcium Phosphate Nanoparticles for Tumor Angiogenesis Inhibition in Breast Cancer

Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.

Synergistic Inhibition of Breast Cancer by Co-Delivery of Vegf Sirna and Paclitaxel Via Vapreotide-Modified Core-Shell Nanoparticles

Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.

Inhibition of Human Hepatocellular Carcinoma Tumor Angiogenesis by Sirna Silencing of VEGF Via Hepatic Artery Perfusion.

Hvegf Sirna Inhibits Initial Growth of A549 Tumor Cells in Nude Mice and Angiogenesis on CAM Assay

Inhibition of VEGF expression in A431 and MDA-MB-231 tumour cells by cationic lipid-mediated siRNA delivery

Combination Antitumor Immunotherapy with VEGF and PIGF Sirna Via Systemic Delivery of Multi-Functionalized Nanoparticles to Tumor-Associated Macrophages and Breast Cancer Cells

A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Efficiently Inhibits Growth of VX2 Cells and VX2 Tumor Model of Hepatocellular Carcinoma in Rabbit by Transarterial Embolization-Mediated Sirna Delivery.

Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

Dual Receptor-Specific Peptides Modified Liposomes As VEGF Sirna Vector for Tumor-Targeting Therapy

A Mesoporous Silica Nanoparticle--pei--fusogenic Peptide System for Sirna Delivery in Cancer Therapy.

Tumor specific delivery with redox-triggered mesoporous silica nanoparticles inducing neovascularization suppression and vascular normalization

Anti-Angiogenic Efficacy of 5 '-Triphosphate Sirna Combining Vegf Silencing and Rig-I Activation in Nsclcs

Co-Delivery of Repurposing Itraconazole and VEGF siRNA by Composite Nanoparticulate System for Collaborative Anti-Angiogenesis and Anti-Tumor Efficacy against Breast Cancer

VEGF-specific siRNAs modified with 2′-deoxy effectively suppress VEGF expression and inhibit growth of nasopharyngeal carcinoma xenograft in a mouse model

Novel Fluorinated Spermine and Small Molecule PEI to Deliver Anti-PD-L1 and Anti-VEGF siRNA for Highly Efficient Tumor Therapy

Vascular endothelial cell growth factor-C small RNA interfering vector down-regulate COX-2, Bel-2 and induce apoptosis in human breast cancer cells

Effective Gene Silencing Mediated by Polypeptide Nanoparticles LAH4-L1-siMDR1 in Multi-Drug Resistant Human Breast Cancer.

Sirna and Chemotherapeutic Molecules Entrapped into a Redox-Responsive Platform for Targeted Synergistic Combination Therapy of Glioma.

VEGF-C siRNA induces apoptosis and inhibits growth of human breast cancer cell line MDA-MB-435